Related Experiment Video

Updated: Sep 22, 2025

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
11:22

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing

Published on: October 15, 2019

29.7K

Role of Gut Microbiota in Pulmonary Arterial Hypertension

Panyun Wu1, Tengteng Zhu1, Zhen Tan1

  • 1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Cellular and Infection Microbiology
|May 23, 2022
PubMed

Insights

Gut dysbiosis, an imbalance in gut bacteria, is increasingly linked to pulmonary arterial hypertension (PAH). Understanding this gut-lung axis may reveal new diagnostic and therapeutic strategies for PAH.

Area of Science:

  • Microbiology
  • Pulmonology
  • Gastroenterology

Background:

  • Gut microbiota and its metabolites are crucial for host homeostasis.
  • Pulmonary arterial hypertension (PAH) is a severe condition with high mortality, characterized by pulmonary vascular remodeling.
  • The pathogenesis of PAH is not fully understood, but emerging evidence implicates the gut microbiome.

Purpose of the Study:

  • To systematically review preclinical and translational data on the association between gut dysbiosis and PAH.
  • To investigate the role of gut dysbiosis in the development of PAH.
  • To explore the potential of gut dysbiosis in PAH diagnosis and treatment.

Main Methods:

  • Systematic review of translational and preclinical studies.
  • Analysis of existing literature on gut microbiota and PAH.
  • Synthesis of data on gut dysbiosis and its impact on pulmonary vascular remodeling.

Main Results:

  • Cumulative evidence suggests a significant role for gut microbiota in PAH pathophysiology.
  • Gut dysbiosis is correlated with the development and progression of PAH.
  • The gut-lung axis represents a potential pathway in PAH pathogenesis.

Conclusions:

  • Gut dysbiosis is a significant factor in PAH.
  • Targeting gut microbiota may offer novel diagnostic and therapeutic avenues for PAH.
  • Further research is needed to resolve existing challenges in understanding the gut dysbiosis-PAH relationship.
Keywords:
gut dysbiosisinflammationpulmonary arterial hypertensiontreatmentvascular remodeling

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

679
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

388

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
302
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
619
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
102
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
263
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
232